Literature DB >> 19324268

Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!

William C Eckelman, Michael R Kilbourn, Chester A Mathis.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19324268     DOI: 10.1016/j.nucmedbio.2008.12.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


× No keyword cloud information.
  11 in total

1.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

2.  High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol.

Authors:  Nicholas T Vandehey; Jeffrey M Moirano; Alexander K Converse; James E Holden; Jogesh Mukherjee; Dhanabalan Murali; R Jerry Nickles; Richard J Davidson; Mary L Schneider; Bradley T Christian
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-30       Impact factor: 6.200

3.  Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging.

Authors:  Jyoti Roy; Margaret E White; Falguni Basuli; Ana Christina L Opina; Karen Wong; Morgan Riba; Anita T Ton; Xiang Zhang; Keith H Jansson; Elijah Edmondson; Donna Butcher; Frank I Lin; Peter L Choyke; Kathleen Kelly; Elaine M Jagoda
Journal:  Mol Imaging Biol       Date:  2021-04-23       Impact factor: 3.488

4.  High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Ulrika Rosenström; Johan Hygum Dam; Mats Larhed; Vladimir Tolmachev; Anna Orlova
Journal:  Contrast Media Mol Imaging       Date:  2017-08-10       Impact factor: 3.161

Review 5.  PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Authors:  Sara S Rinne; Anna Orlova; Vladimir Tolmachev
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 6.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

7.  Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Authors:  Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

8.  Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Authors:  Bogdan Mitran; Zohreh Varasteh; Ayman Abouzayed; Sara S Rinne; Emmi Puuvuori; Maria De Rosa; Mats Larhed; Vladimir Tolmachev; Anna Orlova; Ulrika Rosenström
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

9.  Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.

Authors:  Javad Garousi; Fokko J Huizing; Anzhelika Vorobyeva; Bogdan Mitran; Ken G Andersson; Charles Dahlsson Leitao; Fredrik Y Frejd; John Löfblom; Johan Bussink; Anna Orlova; Sandra Heskamp; Vladimir Tolmachev
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

10.  Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake.

Authors:  Maryam Oroujeni; Sara S Rinne; Anzhelika Vorobyeva; Annika Loftenius; Joachim Feldwisch; Per Jonasson; Vladimir Chernov; Anna Orlova; Fredrik Y Frejd; Vladimir Tolmachev
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.